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Introduction: Fluorine-18 labeled positron emission tomography (PET) tracerswere developed to obtainmore in-
sight into the function of P-glycoprotein (P-gp) in relation to various conditions. They allow research in facilities
without a cyclotron as they can be transportedwith a half-life of 110min. As themetabolic stability of previously
reported tracers [18F]1 and [18F]2was poor, the purpose of this study was to improve this stability using deute-
rium substitution, creating verapamil analogs [18F]1-d4, [18F]2-d4, [18F]3-d3 and [18F]3-d7.
Methods: The following deuterium containing tracerswere synthesized and evaluated inmice and rats: [18F]1-d4,
[18F]2-d4, [18F]3-d3 and [18F]3-d7.
Results: The deuterated analogs [18F]2-d4, [18F]3-d3 and [18F]3-d7 showed increasedmetabolic stability compared
with their non-deuterated counterparts. The increasedmetabolic stability of the methyl containing analogs [18F]
3-d3 and [18F]3-d7 might be caused by steric hindrance for enzymes.
Conclusion: The striking similar in vivo behavior of [18F]3-d7 to that of (R)-[11C]verapamil, and its improvedmet-
abolic stability compared with the other ﬂuorine-18 labeled tracers synthesized, supports the potential clinical
translation of [18F]3-d7 as a PET radiopharmaceutical for P-gp evaluation.
© 2018 . Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
P-glycoprotein (P-gp) is an ATP dependent efﬂux transporter, which
is i.a. located on the luminal side of the blood-brain barrier [1]. As such,
it mediates the transport of structurally diverse compounds from brain
to blood, thereby protecting the brain from xenobiotics. P-gp is the
most studied ATP-binding cassette (ABC) transporter and it is linked
to various neurodegenerative diseases. It has been shown that P-gp
function is diminished in Alzheimer's disease, which may accelerate
the disease process, as it is associatedwith decreased clearance ofβ-am-
yloid from the brain [2]. On the other hand, several studies have shown
increased P-gp function in epilepsy patients, associated with resistance
to anti-epileptic drugs [3]. To obtainmore insight into the function of P-
gp in relation to these and other conditions, positron emission
tomography (PET) can be used to investigate the function of P-gp in
vivo using substrates labeled with positron emitters [4]. (R)-[11C]verap-
amil is a commonly used PET agent for P-gp research, although limited
by its relatively short half-life of 20 min. Originally, verapamil was de-
veloped and used as a calcium channel blocker [5], but it is also a sub-
strate of P-gp.uclearMedicine, VUUniversity
, the Netherlands.
.
pen access article under the CC BY-NRecently, two ﬂuorine-18 labeled positron emission tomography
(PET) tracers were developed [6] ([18F]1 and [18F]2, Fig. 1) to image
the function of P-gp in the brain, based on the chemical structure of
verapamil. Clearly, these tracers could be useful in clinical studies of
Alzheimer's disease or epilepsy, where alterations in P-gp function
could be detected in a PET scan by increased or decreased brain uptake.
Despite their high speciﬁcity for P-gp, a disadvantage of these tracers
was their poor metabolic stability, as this may compromise quantiﬁca-
tion, decrease the signal-to-noise ratio and complicate interpretation.
Themetabolic pathway of verapamil has been studied in detail [7,8].
Different metabolites were identiﬁed and the most important initial
metabolites were D-617, norverapamil and D-703. The metabolites
and corresponding enzymes are depicted in Fig. 2 [9, 10]. Previous PET
studies have shown the formation of corresponding radiolabeled me-
tabolites of (R)-[11C]verapamil in vivo [11].
It is known that N-demethylation of verapamil by cytochrome P450
enzyme, yielding the metabolite norverapamil occurs via the hydrogen
atom transfer (HAT) mechanism [12]. Within this reaction, ﬁrst a
hydrogen atom (H) is abstracted creating a radical carbon atom. Next,
an alcohol is formed which is cleaved of to form formaldehyde and a
secondary amine. Deuterium substitution of the methyl group could
be used to slow down this reaction. Cleavage of the covalent bond of
carbon (C) with deuterium (D) requires greater energy than cleavage
of the bond with hydrogen, due to the higher mass of deuterium,C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chemical structures of deuterated (nor-)verapamil analogs, with measured Log D values.
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quency and, thus, lower zero-point energy than an analogous C\\H
bond. This results in higher activation energy and slower rate for C\\D
bond cleavage. This rate effect is referred to as the primary deuterium
isotope effect [13–15].
The deuterium substitution approach has been used on a number of
occasions to ﬁne-tune properties of new pharmaceuticals, primarily
related to metabolic stability. The ﬁrst approval of a deuterium contain-
ing drug was provided by the FDA for deutetrabenazine, issued 3rd of
April 2017 [16,17]. In addition, in developing new PET tracers, deute-
rium has occasionally been used to alter properties. The ﬁrst and most
well-known deuterated PET tracer is [11C]L-deprenyl-D2, which showed
slower binding to its target MAO B than the original hydrogen
compound resulting in a reduced rate of trapping in (brain) tissue and
to improve sensitivity [18]. Multiple deuterated analogs of [11C]- and
[18F]-choline showed improved protection against choline oxidation
[19,20]. Another example is [18F]deuteroaltanserin, which showed 29%
higher ratios of parent tracer to radiometabolites in plasma, compared
with [18F]altanserin [21].
In this study, four deuterium substituted analogs were synthesized
and evaluated for metabolic stability and in vivo behavior. The purpose
of this work is to develop a stable ﬂuorine-18 PET tracer for P-gp
evaluation, to gain more insight in the metabolic pathways and to
investigate which groups are more prone to metabolism.Fig. 2.Metabolic pathway of (R) [11C]verapam2. Materials & methods
2.1. General
Chemicals and solvents were purchased from commercial sources
Sigma-Aldrich (Zwijndrecht, the Netherlands), Fluorochem (Hadﬁeld
Derbyshire, UK), ABCr GmbH (Karlsruhe, Germany) and Biosolve
(Valkenswaard, the Netherlands) without further puriﬁcation unless
stated otherwise. Deuterated starting materials ethylene-d4 glycol, 2-
bromoethanol-1,1,2,2-d4 and Iodomethane-d3 had an isotopic purity
of 98, 98 and ≥99.5 atom % D, respectively. (R)-desmethyl-verapamil
was kindly donated by Abbott Laboratories (Lake Bluff, IL, USA).
Dichloromethane (DCM), 1,2-dichloroethane (DCE), methanol
(MeOH) and dimethylformamide (DMF) were dried over 3 Åmolecular
sieves, for at least 24 h prior to use. Tetrahydrofuran (THF) was ﬁrst
distilled from LiAlH4 and then dried over 3 Å molecular sieves. Thin
layer chromatography (TLC) was performed on Merck (Darmstadt,
Germany) precoated silica gel 60 F254 plates. Spots were visualized by
UV quenching or ninhydrin. Column chromatography was carried out
either manually by using silica gel 60 Å (Sigma-Aldrich) or on a Buchi
(Flawil, Switzerland) sepacore system (comprising of a C-620 control
unit, a C-660 fraction collector, 2 C-601 gradient pumps and a C-640
UV detector) equipped with Buchi sepacore prepacked ﬂash columns.
1H and 13C nuclear magnetic resonance (NMR) spectra were recordedil as adapted from Luurtsema et al. [11].
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respectively) with chemical shifts (δ) reported in ppm relative to the
solvent. Electrospray ionization mass spectrometry (ESI-MS) was
carried out using a Bruker microTOF-Q instrument in positive ion
mode (capillary potential of 4500 V). Solid-phase extraction cartridges
(tC18 plus and Alumina N)were purchased fromWaters Corp. (Milford,
MA, USA).
Semi-preparative HPLC was performed on a Jasco PU-2089 pump
station (Easton, MD, USA) equipped with either a Luna C18(2) column
(10 μm, 250 mm × 10 mm, Phenomenex, California, USA) using H2O/
MeCN/TFA (60:40:0.2, %v/v/v, method: A) or 5 mM K3PO4/MeCN
(28:72, %v/v, pH = 10.0, method: B) as eluent, or a Grace Alltima
column (10 μm, 250 mm × 22 mm; Hichrom, Theale, Berkshire, UK)
using H2O/MeCN/TFA (50:50:0.1, %v/v/v, method: C) as eluent at a
ﬂow rate of 4 mL·min−1, a Jasco UV-2075 Plus UV detector (λ =
254 nm), a custom made radioactivity detector and Jasco ChromNAV
CFR software (version 1.14.01) for data acquisition. Quantitative
analysis was performed using an HPLC system of Jasco containing a
PU-2089 pump station equipped with a Grace Alltima C18 column
(5 μm, 250 mm × 4.6 mm) using H2O/MeCN/DIPA (40:60:0.1, %v/v/v,
method: D), H2O/MeCN/TFA (50:50:0.1, %v/v/v, method: E) or H2O/
MeCN/TFA (60:40:0.1, %v/v/v, method: F) as eluent at a ﬂow rate of
1mL·min−1, with a Jasco UV-2075 UV detector (λ=232 nm) and a So-
dium Iodide (NaI) radioactivity detector (Raytest, Straubenhardt,
Germany). Chromatogramswere acquired using Raytest GINA Star soft-
ware (version 5.01).
Metabolite analysis was performed on Dionex (Sunnyvale, CA,
USA) UltiMate 3000 HPLC equipment with Chromeleon software
(version 6.8). A LUNAC8 (5 μm, 250mm× 10mm, Phenomenex (Tor-
rance, CA, USA)) column was used (method G) using 5 mM NH4OAc/
MeCN (1:1, %v/v, pH = 4.2) as eluent at a ﬂow rate of 3.5 mL·min−1.
2.1.1. 2-Bromoethyl-1,1,2,2-d4 4-methylbenzenesulfonate (6)
4-Methylbenzene-1-sulfonyl chloride (924 mg, 4.85 mmol) was
dissolved in DCM (3 mL) at 0 °C. Et3N (0.675 mL, 4.85 mmol) and 2-
Bromoethanol-1,1,2,2-d4 (0.275 mL, 3.88 mmol) were added drop-wise
to the reaction mixture. The mixture was stirred for 1 h at 0 °C. The reac-
tion mixture was brought to room temperature, washed with water and
brine and dried over Na2SO4. The solvent was evaporated in vacuo, and
the residue was puriﬁed by ﬂash column chromatography (10% EtOAc
in hexane), obtaining the 2-bromoethanol-1,1,2,2-d4-methylbenzene-1-
sulfonyl product (0.988 mg, 3.53 mmol, 91% yield) as colorless oil. 1H
NMR (CDCl3) δ 7.83 [2H, d, J = 8.3 Hz, SO2-CHAR], 7.38 [2H, d, J =
8.0 Hz, CH3-CHAR], 2.48 [3H, s, TsCH3] 13C NMR (CDCl3) δ 145.21,
132.67, 129.95, 127.95, 21.65 ESI-HRMS: calculated for C9H7d4BrO3S:
281.9863, 282.9936 [M+ H]+ and 304.9749 [M+ Na]+ found.
2.1.2. Ethane-1,2-diyl-d4 bis(4-methylbenzenesulfonate) (7)
Ethylene-d4 glycol (0.19mL, 3.40mmol)was dissolved inDCM(5mL)
and brought to 0 °C, and then 4-methylbenzene-1-sulfonyl chloride
(2.19 g, 11.5 mmol) and triethylamine (1.58 mL, 11.3 mmol) were
added. The reaction mixture was stirred starting from 0 °C to room tem-
perature, overnight. The reaction was quenched with water, and crude
product was extracted with DCM, washed with water and brine, and
dried over Na2SO4 after which the solvent was evaporated in vacuo. The
brown solid was puriﬁed by ﬂash column chromatography (20–50%
EtOAc in hexane) resulting in a white powder (1.33 g, 3.55 mmol, quan-
titative yield). 1H NMR (CDCl3) δ 7.73 [4H, d, J=8.3 Hz, SO2-CHAR], 7.33
[4H, d, J=8.1 Hz CH3-CHAR], 2.46 [6H, s, CH3]. 13C NMR (CDCl3) δ (ppm)
145, 132, 130, 128, 22. ESI-HRMS: calculated for C16H14d4O6S2: 374.0796,
375.0900 [M+ H]+ and 397.0728 [M+ Na]+ found.
2.1.3. 2-(4-(2-((tert-Butoxycarbonyl)amino)ethyl)-2-methoxyphenoxy)
ethyl-1,1,2,2-d4 4-methylbenzenesulfonate (9)
tert-Butyl 4-hydroxy-3-methoxyphenethylcarbamate (417mg, 1.56mmol)
was dissolved in DMF (50 mL) and cesium carbonate (1.02 g, 3.12 mmol)and d4-ethane-1,2-diyl bis(4-methylbenzenesulfonate) (1.17 g, 3.12 mmol)
were added. The yellow clear mixture was stirred at room temperature
and after 4 h it turned into a green cloudy mixture. The reaction was
quenched with water. The crude product was extracted twice with
EtOAc, washed with brine, dried over Na2SO4 and the solvent was
evaporated in vacuo. The yellow oil was puriﬁed by ﬂash column
chromatography (20% EtOAc in hexane) resulting in a white powder
(754 mg, 1.60 mmol, quantitative yield). 1H NMR (CDCl3) δ 7.82 [2H, d,
J = 8.4 Hz, SO2-CHAR], 7.33 [2H, d, J = 8.4 Hz CH3-CHAR], 6.77–6.65
[3H, m, CHAR], 4.55 [1H, br s, NH], 3.82 [3H, s, OCH3], 3.34 [2H, q, J =
6.5, NHCH2CH2], 2.73 [2H, t, J = 7.1, NHCH2CH2], 2.45 [3H, s, TsCH3],
1.44 [9H, s, Boc]. 13C NMR (CDCl3) δ 155.82, 149.88, 146.01, 144.83,
133.29, 132.87, 129.80, 127.99, 120.78, 115.32, 112.80, 79.22, 55.88,
41.81, 35.78, 28.39, 21.64. ESI-HRMS: calculated for C23H27d4NO7S:
469.2072; 470.2179 [M+ H]+ and 492.2010 [M+ Na]+ found.2.1.4. 2-(4-(2-Aminoethyl)-2-methoxyphenoxy)ethyl-1,1,2,2-d4 4-
methylbenzenesulfonate (10)
2-(4-(2-((tert-Butoxycarbonyl)amino)ethyl)-2-methoxyphenoxy)
ethyl-1,1,2,2-d4 4-methylbenzenesulfonate (61 mg, 0.13 mmol) was
dissolved in DCM (5 mL) and TFA (5 mL) was added. The reaction mix-
ture was stirred at room temperature for 1 h after which it was diluted
with DCM and the solvent was evaporated in vacuo. The light brown oil
was puriﬁed by ﬂash column chromatography (4–10% MeOH in DCM)
to obtain the desired white crystals (52 mg, 0.14 mmol, quantitative
yield). 1H NMR (MeOD) δ 7.80 [2H, d, J= 8.1 Hz, SO2-CHAR], 7.42 [2H,
d, J = 8.1 Hz CH3-CHAR], 6.88–6.73 [3H, m, CHAR], 3.82 [3H, s, OCH3],
3.15 [2H, q, J= 7.8 Hz, NHCH2CH2], 2.88 [2H, t, J= 7.8 Hz, NHCH2CH2]
, 2.44 [3H, s, TsCH3]. 13C NMR (MeOD) δ 151.68, 148.28, 146.64,
134.38, 132.09, 131.18, 129.16, 122.23, 116.70, 114.30, 56.64, 42.12,
34.28, 21.74. ESI-HRMS: calculated for C18H19d4NO5S: 369.1548;
370.1608 [M+ H]+ found.2.1.5. (R)-2-(4-(2-((tert-butoxycarbonyl)(4-cyano-4-(3,4-dimethoxyphenyl)-
5-methylhexyl)amino)ethyl)-2-methoxyphenoxy)ethyl-1,1,2,2-d4 4-
methylbenzenesulfonate (17)
Na2SO4 (55 mg, 0.39 mmol) and (R)-2-(3,4-dimethoxyphenyl)-2-
isopropyl-5-oxopentanenitrile (151 mg, 0.547 mmol) in 1.7 mL DCE
were added to a solution of 2-(4-(2-aminoethyl)-2-methoxyphenoxy)
ethyl-1,1,2,2-d4 4-methylbenzenesulfonate [6] (223 mg, 0.604 mmol)
in 1.7 mL DCE. The reaction mixture was stirred at room temperature
overnight under N2. Sodium triacetoxyhydroborate (132 mg,
0.623 mmol) was added to the mixture and stirred for 1.5 h at room
temperature. The reaction was quenched with 1 M NaHCO3, extracted
with EtOAc (10 mL), washed with water (2×) and brine, organic layers
were dried over Na2SO4, and used as such in the next step. Di-tert-butyl
dicarbonate (185 mg, 0.848 mmol) and triethylamine (120 μL,
0.866 mmol) were added to diluted crude product and stirred at room
temperature for 1.5 h. The reaction mixture was diluted with EtOAc,
washed with water and brine, dried over Na2SO4, and solvent was re-
moved in vacuo. The crude mixture was puriﬁed by ﬂash column chro-
matography (30–50% EtOAc/Hex) to obtain the puriﬁed product as
colorless oil (37 mg, 0.051 mmol, 13% yield). 1H NMR (CDCl3) δ 7.82
[2H, d, J= 8.2 Hz, SO2-CHAR], 7.33 [2H, d, J= 8.2 Hz, CH3-CHAR], 6.89–
6.62 [6H, m, CHAR], 3.88 [3H, s, OCH3], 3.87 [3H, s, OCH3], 3.80 [3H, s,
OCH3], 3.29–2.99 [4H, m, CH2NCH2], 2.67 [2H, br s, NCH2CH2Ar], 2.44
[3H, s, TsCH3], 2.06 [2H, m, CH2CH2CH2], 1.80–1.55 [3H, m, CH(CH3)2
and CCH2], 1.43 [9H, m, Boc], 1.17 and 0.78 [3H each, d, J = 6.3 Hz, CH
(CH3)2]. 13C NMR (CDCl3) δ 149.69, 148.96, 148.43, 148.21, 145.83,
144.83, 133.40, 132.75, 130.36, 129.79, 127.97, 120.74, 118.65, 115.14,
112.76, 110.97, 109.26, 79.38, 55.90, 55.83, 55.82, 49.08, 48.67, 47.27,
37.87, 35.14, 34.79, 28.36, 24.62, 21.64, 18.90, 18.51. ESI-HRMS: calcu-
lated for C39H48d4N2O9S: 728.3645, 729.4104 [M + H]+ and 751.3935
[M+ Na]+ found.
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carbamate (11)
2-(4-(2-((tert-Butoxycarbonyl)amino)ethyl)-2-methoxyphenoxy)
ethyl-d4 4-methylbenzenesulfonate (471 mg, 1.00 mmol) and TBAF
(446 mg, 1.71 mmol) were co-evaporated three times with dry
acetonitrile to remove any water. Compounds were dissolved in aceto-
nitrile (5 mL) and added to a closed reaction vial. The reaction mixture
was stirred at 85 °C in heatblock for 4 h. Solvent was evaporated and
crude mixture was puriﬁed by ﬂash column chromatography (10–25%
EtOAc in hexane) to obtain the desired clear oil (254 mg, 0.800 mmol,
80%). 1H NMR (CDCl3) δ 6.88–6.71 [3H, m, CHAR], 4.55 [1H, br s, NH2],
3.87 [3H, s, OCH3], 3.36 [2H, q, J = 6.6 Hz, NHCH2CH2], 2.75 [2H, t, J=
7.0, NHCH2CH2], 1.44 [9H, s, Boc]. 13C NMR (CDCl3) δ 155.71, 149.52,
146.15, 132.70, 120.51, 114.34, 112.44, 78.85, 55.61, 41.65, 35.54,





(253 mg, 0,797 mmol) was dissolved in DCM (12 mL), TFA (12 mL)
was added and the mixture was stirred at room temperature for 1 h.
Reaction mixture was diluted with DCM and solvent was evaporated
under vacuo. Crudemixturewas puriﬁed by ﬂash column chromatogra-
phy (3–5%MeOH in DCM) to obtain the desired product as a white solid
(174 mg, 0.800 mmol, quantitative yield). 1H NMR (MeOD) δ 6.95–6.78
[3H, m, CHAR], 3.85 [3H, s, OCH3], 3.16 [2H, t, J = 7.6 Hz, NHCH2], 2.90
[2H, t, J = 8.0 Hz, NHCH2CH2]. 13C NMR (CDCl3) δ (ppm) 151.57,
148.78, 131.72, 122.32, 116.09, 114.20, 56.61, 42.15, 34.30. ESI-HRMS:




(174 mg, 0.800 mmol) was dissolved in dry MeOH (3 mL) and Na2SO4
(600 mg, 4.2 mmol) was added. (R)-2-(3,4-dimethoxyphenyl)-2-iso-
propyl-5-oxopentanenitrile (147 mg, 0.534 mmol) was dissolved in
dry MeOH (1.4 mL), added to the mixture, which was stirred at room
temperature overnight under nitrogen. Sodium triacetoxyhydroborate
(170 mg, 0.800 mmol) was added and stirred at room temperature for
2 h. The reaction was quenched with 1 M NaHCO3 and extracted with
EtOAc, washed with H2O and brine, dried over Na2SO4 and the solvent
was evaporated in vacuo. The crude oil was puriﬁed by column chroma-
tography (2–7% MeOH in DCM) to obtain the desired product (30 mg,
0.063 mmol, 12% yield). 1H NMR (CDCl3) δ 6.96–6.68 [6H, m, CHAR],
3.89 [3H, s, OCH3], 3.87 [3H, s, OCH3], 3.84 [3H, s, OCH3], 2.89 [4H, m,
CH2NCH2CH2], 2.75 [2H, t, J = 6.9 Hz, NCH2CH2], 2.20 and 1.93 [1H
each, dt, J= 12.0 and 4.5, CCH2], 2.07 [1H, sept, J= 6.8 Hz, CH(CH3)2],
1.67 and 1.32 [1H each, m, CH2CH2CH2], 1.18 and 0.79 [3H each, d,
J = 6.6, CH(CH3)2]. 13C NMR (CDCl3) δ 149.85, 149.05, 148.35, 146.60,
131.87, 129.99, 121.14, 120.57, 118.63, 114.59, 112.58, 111.06, 109.37,
55.97, 55.92, 55.81, 49.53, 47.97, 37.87, 35.02, 33.78, 23.91, 18.85,






d4 (219 mg, 0.592 mmol) and (R)-2-(3,4-dimethoxyphenyl)-2-isopropyl-
5-oxopentanenitrile (110 mg, 0.403 mmol) were stirred together with
Na2SO4 (1.5 g) in DCE (3 mL) under nitrogen overnight. The reaction
mixture turned light yellow and sodium triacetoxyhydroborate (137 mg,
0.645 mmol) was added and the resulting mixture was stirred at room
temperature for 2 h. The reaction was quenched with 1 M NaHCO3, ex-
tracted with EtOAc, washed with water and brine, organic layers weredried over Na2SO4, and used as such in next step. Iodomethane-d3
(45.0 μL, 0.723 mmol) and DiPEA (200 μL, 1.15 mmol) were added to
the reactionmixture and stirred overnight at room temperature. The re-
action mixture was diluted with EtOAc, washed with water and brine,
dried over Na2SO4 and solvent was removed in vacuo. The crude mix-
ture was puriﬁed by ﬂash column chromatography (2% MeOH in
DCM) and HPLC (method C) to obtain the product as a white solid
(5 mg, 0.007 mmol, 2% yield). 1H NMR (MeOD) δ 7.81 [2H, d, J =
8.0 Hz, SO2-CHAR], 7.42 [2H, d, J = 8.2 Hz, CH3-CHAR], 7.04–6.67 [6H,
m, CHAR], 3.84 [3H, s, OCH3], 3.82 [3H, s, OCH3], 3.80 [3H, s, OCH3],
3.15–2.88 [4H, m, CH2NCH2], 2.45 [3H, s, TsCH3], 2.22–2.03 [3H, m CH
(CH3)2 and CCH2], 1.75 and 1.38 [1H each, br s, CH2CH2CH2], 1.31 [2H,
br s, NCH2CH2Ar], 1.22 and 0.79 [3H each, d, J = 6.6 Hz, CH(CH3)2].
13C NMR (CDCl3) δ 151.78, 151.16, 150.51, 148.49, 146.65, 134.48,
131.46, 131.26, 131.20, 129.21, 122.21, 122.16, 120.56, 116.64, 114.27,
112.98, 110.94, 56.79, 56.70, 56.58, 56.51, 38.88, 35.48, 33.24, 30.88,
23.91, 22.34, 21.76, 19.50, 19.03. ESI-HRMS: calculated for





(341 mg, 0.935 mmol) and (R)-2-(3,4-dimethoxyphenyl)-2-isopropyl-5-
oxopentanenitrile (177 mg, 0.644 mmol) were stirred together with
Na2SO4 (1.5 g) in DCE (5 mL) under nitrogen overnight. The reaction
mixture turned light yellow and sodium triacetoxyhydroborate
(206 mg, 0.971 mmol) was added and this mixture was stirred at room
temperature for 1.5 h. The reactionwas quenchedwith 1MNaHCO3, ex-
tracted with EtOAc, washed with water and brine, after which organic
layers were dried over Na2SO4 and used as such in the next step.
Iodomethane-d3 (65.0 μL, 1.04 mmol) and DiPEA (290 μL, 1.66 mmol)
were added to the reaction mixture and stirred overnight at room tem-
perature. The reaction mixture was diluted with EtOAc, washed with
water and brine, dried over Na2SO4 and solvent was removed in vacuo.
The crude mixture was puriﬁed by ﬂash column chromatography (2%
MeOH in DCM) and HPLC (method C) to obtain the product as a white
solid (12 mg, 0.019 mmol, 3.0% yield). 1H NMR (CDCl3) δ 7.81 [2H, d,
J = 8.2 Hz, SO2-CHAR], 7.42 [2H, d, J = 8.2 Hz, CH3-CHAR], 7.04–6.67
[6H, m, CHAR], 4.32 [2H, t, J = 4.4 Hz, CH2CH2OTs], 4.15 [2H, t, J =
4.4 Hz, CH2CH2OTs], 3.84 [3H, s, OCH3], 3.82 [3H, s, OCH3], 3.80 [3H, s,
OCH3], 3.16–2.89 [4H, m, CH2NCH2], 2.45 [3H, s, TsCH3], 2.22–2.04 [3H,
m, CH(CH3)2 and CCH2], 1.75 and 1.37 [1H each, br s, CH2CH2CH2], 1.31
[2H, br s, NCH2CH2Ar], 1.22 and 0.79 [3H each, d, J= 6.6 Hz, CH(CH3)2]
. 13C NMR (CDCl3) δ 151.76, 151.14, 150.49, 148.46, 146.66, 134.45,
131.45, 131.32, 131.20, 129.21, 122.20, 122.16, 120.56, 116.67, 114.27,
112.96, 110.93, 70.35, 68.61, 56.79, 56.70, 56.58, 56.50, 38.88, 35.48,
33.24, 30.87, 23.90, 22.38, 21.76, 19.50, 19.03. ESI-HRMS: calculated for




(147 mg, 0.534 mmol) was dissolved in 1.4 mL MeOH and added to a
suspension of 2-(4-(2-ﬂuoroethoxy)-3-methoxyphenyl)ethane-d4-
amine (174 mg, 0.801 mmol) and Na2SO4 (613 mg) in 3 mL dry
MeOH. The reactionmixturewas stirred overnight at room temperature
under nitrogen. Sodium triacetoxyhydroborate (170 mg, 0.801 mmol)
was added and the mixture was stirred again at room temperature for
2 h. The reaction was quenched with 1 M NaHCO3 and extracted with
EtOAc, washed with water and brine, dried over Na2SO4 and solvent
was removed in vacuo to an oil. The crude mixture was puriﬁed by
ﬂash column chromatography (2–7% MeOH in DCM) to obtain the de-
sired product as a light brown oil (30 mg, 0.063 mmol, 12% yield). 1H
NMR (CDCl3) δ 6.94–6.66 [6H, m, CHAR], 4.77 [2H, dt, J = 47.4 and
4.2 Hz, CH2CH2F], 4.25 [2H, dt, J = 27.8 and 4.3 Hz, CH2CH2F], 3.89
Scheme 1. Reagents and conditions: TsCl, Et3N, DCM, 0 °C, 1 h (4 to 6) or 16 h (5 to 7).
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CH2NCH2CH2], 2.38 [2H, m, NCH2CH2], 2.13 and 1.84 [1H each, dt, J =
12.0 and 4.2, CCH2], 2.06 [1H, sept, J = 6.7 Hz, CH(CH3)2], 1.56 and
1.16 [1H each, m, CH2CH2CH2] 1.20 and 0.81 [3H each, d, J = 6.8, CH
(CH3)2]. 13C NMR (CDCl3) δ 149.65, 148.91, 148.17, 146.09, 134.25,
130.57, 121.43, 120.54, 118.60, 114.55, 112.67, 110.97, 109.40, 82.69,
81.33, 68.72, 68.56, 59.27, 56.78, 55.93, 55.92, 55.84, 37.91, 35.56,
33.14, 23.27, 18.95, 18.58. ESI-HRMS: calculated for C28H36d3FN2O4:




[18F]F−was produced by the 18O(p,n)18F nuclear reaction using an
IBA (Louvain-la-Neuve, Belgium) Cyclone 18/9 cyclotron. Radioactivity
levels were measured using a Veenstra (Joure, The Netherlands) VDC-
405 dose calibrator. Radiochemistry was carried out in homemade, re-
motely controlled synthesis units [22]. After irradiation, [18F]ﬂuoride
was trapped on a PS-HCO3 column and eluted using 1 mL MeCN/H2O
(9:1, %v/v) containing Kryptoﬁx 2.2.2 (3 mg, 35 μmol) and K2CO3
(2 mg, 14 μmol) into a screw cap reaction vial. The [18F]K222/KF/K2CO3
complex was dried at 90 °C under a Helium ﬂow of 50 mL·min−1 and
reduced pressure for 6 min. 0.5 mL MeCN was added and the complex
was dried for 3 min resulting in a white tarnish on the bottom of the
vial. Precursor 6 (10 mg, 36 μmol) was dissolved in 0.5 mL DMF and
added to the vial with the dried complex. This reaction mixture was
heated to 90 °C. After 10 min, the formed volatile intermediate 1-
bromo-2-[18F]ﬂuoroethane-d4 was distilled at 100 °C through a
preheated silver triﬂate column at 200 °C, resulting in [18F]
ﬂuoroethyl-d4-triﬂate, which was bubbled to the second reaction vial
containing a reaction mixture with (R)-desmethyl-norverapamil
(1.5 mg, 3.4 μmol), K2CO3 (1.5 mg, 11 μmol) and a stirring bar in
0.5mLACNat 0 °C (Scheme3). After distillation, the reactionwas stirred
for 15min at 120 °C, quenchedwith 1mL ofwater and puriﬁed by semi-
preparative HPLC (method B). The product eluted at 8 min, and the
product fraction was collected for 1.5 min, which was diluted with
40 mL of water. The mixture was passed through a Sep-Pak Plus tC18
cartridge and subsequently rinsed with 20 mL water. The product was
eluted from the Sep-Pak Plus tC18 cartridge with 1 mL ethanol (96%)Scheme 2. Reagents and conditions: i) 7, Cs2CO3, DMF, r.t.,and was diluted with a solution of 7.11 mM NaH2PO4 in 0.9% NaCl (w/
v in water), pH 5.2 resulting in a ﬁnal solution with 5% ethanol. The ra-
diochemical purity was determined by analytical HPLC (method D) to
be N99% and the molar radioactivity was 201 ± 88 GBq·μmol−1 (n =
3). The radiochemical yield was 2.64 ± 2.26%, decay corrected (DC)




Precursor 17 (1.0 mg, 1.3 μmol) was dissolved in 0.5 mL MeCN, added
to the dried [18F]K222/KF/K2CO3 complex, and heated at 90 °C for 15 min.
The reaction mixture was cooled down to room temperature and TFA
(0.2 mL, 2.7 μmol) was added. After 10 min, the reaction was quenched
with 0.9 mL of 2.5 M NaOH and puriﬁed by semi-preparative HPLC
(method A). The product eluted at 15 min, and the product fraction of
1.5minwas dilutedwith 40mLofwater. Thismixturewas passed through
the Sep-Pak Plus tC18 cartridge and subsequently rinsed with 20 mL
water. The product was eluted with 1 mL ethanol (96%) and diluted with
a solution of 7.11 mM NaH2PO4 in 0.9% NaCl (w/v in water), pH 5.2
resulting in a ﬁnal solution with 5% ethanol, with a radiochemical purity
of N99% determined by analytical HPLC (method F). The molar radioactiv-
ity was 104± 48 GBq·μmol−1 (n=2) and the radiochemical yield 6.1±





Precursor 19 (0.5 mg, 0.8 μmol) was dissolved in 0.5 mL MeCN,
added to the dried [18F]K222/KF/K2CO3 complex and heated at 90 °C
for 15min. The reactionmixturewas passed through a Sep-PakAlumina
N light cartridge and rinsed with 1.5 mLMeCN and 1 mL air. The eluate
was diluted with 1.5 mL water and puriﬁed by semi-preparative HPLC
(method A). The product eluted at 15 min, and the product fraction of
1.5 min was diluted with 40 mL of water. The mixture was passed
through the Sep-Pak Plus tC18 cartridge and subsequently rinsed with
20 mL water. The product was eluted with 1 mL ethanol (96%) and di-
luted with a solution of 7.11 mM NaH2PO4 in 0.9% NaCl (w/v in
water), pH 5.2 resulting in a ﬁnal solutionwith 5% ethanol, with a radio-
chemical purity of N99.5% determined by analytical HPLC (method E).
The molar radioactivity was 125 GBq·μmol−1 (n = 1) and the radio-




[18F]3-d7was prepared using an identical procedure as for [18F]3-d3,
starting with precursor 16 (0.5 mg, 0.8 μmol). The radiochemical purity
was N99.5% determined by analytical HPLC (method E). The molar ra-
dioactivity was 91.3 ± 25.5 GBq/μmol (n = 5) and the radiochemical
yield was 4.90 ± 3.86% DC from start of synthesis (n = 5).4 h; ii) TBAF, MeCN, 85 °C, 4 h; iii) TFA, DCM, r.t., 1 h.
Scheme3.Reagents and conditions: i) (R) aldehyde 15 [6], NaBH(OAc)3, Na2SO4, DCE, r.t., 18 h. For12directly to 18. Next step for 10, 13 and 14 to form16, 19 and 20, respectively: ii) CD3I,
DiPEA, r.t., 18 h. Only for 10 to form 17: Boc2O, Et3N, r.t., 1.5 h.
Scheme 4. Reagents and conditions: i) 18F/K2.2.2/K+, DMF, 90 °C, 15 min; ii) AgOTf, 200 °C, 15 min; iii) norverapamil, K2CO3, MeCN, 120 °C, 15 min.
Scheme 5. Reagents and conditions: i) 18F/K2.2.2/K+, MeCN, 90 °C, 15 min; only for [18F]2 d4: ii) TFA, r.t., 10 min.
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The distribution of the tracers between equal volumes of 0.2Mphos-
phate buffer (pH = 7.4) and 1-octanol was measured in triplicate at
room temperature. 1 mL of a 1–5 MBq·mL−1 solution of the ﬂuorine-
18 labeled tracers in 0.2 M phosphate buffer (pH= 7.4) was vigorously
mixed with 1 mL of 1-octanol for 1 min at room temperature using a
vortex. After 30min,ﬁve samples of 100 μLwere taken fromboth layers,
avoiding cross-contamination. To determine recovery, 5 samples of
100 mL were taken from the 1–5 MBq·mL−1 solution. All samples
were counted for radioactivity. The Log Doct,7.4 value was calculated
according to Log Doct,7.4 = 10Log(Aoct/Abuffer), where Aoct and Abuffer rep-
resent average radioactivity of 5 1-octanol and 5 buffer samples,
respectively [23].
2.4. Animals
Healthy male Wistar rats were obtained from Harlan Netherlands
B.V. (Horst, the Netherlands) and male FVB wild-type mice and
Mdr1a/b(−/−) mice developed from the FVB line were purchased from
Taconic (Hudson, USA). All animals were housed in groups of four to
six per cage under standard conditions (24 °C, 60% relative humidity,
12-h light/dark cycles) and provided with water and food (Teklad
Global 16% Protein Rodent Diet, Harlan, Madison, WI, USA) ad libitum.
All animal experiments were performed in compliance with Dutchlaws on animal experimentation (‘Wet op de proefdieren’, Stb 1985,
336) and after approval by the local animal ethics committee.
2.5. Metabolite analysis
Under isoﬂurane anesthesia, healthy Wistar rats (198–286 g) re-
ceived tail vein injection of 36.8 ± 5.7, 30.2 ± 5.0, 24.4 ± 5.2 or
38.6 ± 6.1 MBq of [18F]1-d4, [18F]2-d4, [18F]3-d3 or [18F]3-d7, respec-
tively, in 0.2–0.4mL. After injection, rats were conscious for the allowed
time (except for the animals of the 5min time point,whichwere left un-
conscious for the whole time) and sacriﬁced under isoﬂurane anesthe-
sia at 5, 15 or 60 min (n= 3 for each time point). Blood samples were
collected via a heart puncture, and the brain was removed from the
skull and cut in half. Blood was collected in a heparin tube and centri-
fuged for 5 min at 4000 rpm (Hettich universal 16, Depex B.V., the
Netherlands). Plasma was separated from blood cells, 1 mL plasma
was loaded onto a Sep-Pak tC18 cartridge (Waters, Etten-Leur, the
Netherlands), and the cartridge was washed with 20 mL of water. This
eluate was deﬁned as the polar radiolabeled metabolite fraction. Next,
the Sep-Pak cartridge was eluted with 1.5 mL of methanol. This eluate
was deﬁned as the non-polar fraction, and also contains the parent
tracer. It was analyzed using HPLC (method G). The recovery from the
Sep-pak procedure was N85% and rest activity was not taken into ac-
count. One half of the brain was counted for activity and the other half
was homogenized with an ultrasonic homogenizer (Braunsonic 1510,
Table 1
Parent tracer and radiolabeled metabolite fractions in plasma (% of total radioactivity, mean ± SD; after intravenous injection of tracers under isoﬂurane anesthesia); for chemical struc-
tures, see Fig. 1.
Min [18F]1 [18F]1 d4 [18F]2 [18F]2 d4 [18F]3 d3 [18F]3 d7
Parent tracer 5 46 ± 14% 42 ± 12% 20 ± 3% 36 ± 6% 34 ± 5% 45 ± 3%
15 19 ± 2% 23 ± 3% 8 ± 3% 15 ± 2% 18 ± 4% 24 ± 2%
60 3 ± 1% 1 ± 0.3% 4 ± 1% 4 ± 1% 6 ± 1% 7 ± 1%
Non-polar metabolites 5 5 ± 2% 8 ± 4% 5 ± 3% 5 ± 6% 6 ± 1% 19 ± 3%
15 9 ± 3% 9 ± 0.4% 5 ± 1% 4 ± 1% 7 ± 0.2% 23 ± 3%
60 5 ± 0.5% 8 ± 1% 3 ± 1% 5 ± 1% 5 ± 1% 13 ± 1%
Polar metabolites 5 49 ± 11% 47 ± 7% 75 ± 3% 59 ± 4% 60 ± 5% 36 ± 5%
15 71 ± 2% 68 ± 3% 87 ± 1% 81 ± 2% 75 ± 4% 52 ± 5%
60 92 ± 1% 92 ± 1% 93 ± 2% 91 ± 1% 89 ± 2% 80 ± 3%
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quently centrifuged at 4000 rpm for 5 min. Separated supernatants
were analyzed using HPLC.
Statistical analysis was performed using Graphpad PRISM (v 5.02,
Graphpad Software Inc.). The metabolic stability (% parent tracer) of
the deuterated tracers was compared to the non-deuterated analogs
using a two-tailed unpaired t-test. Differences were considered signiﬁ-
cant if p b 0.05.
2.6. PET imaging and data analysis
Mice (25–32 g; Mdr1a/b(−/−) mice: n = 3; WT mice: n = 4) were
anesthetized via a nose mask using 2% isoﬂurane in oxygen at a rate of
1 L·min−1. One hour prior to each study, a jugular vein was cannulated
for administration of the tracer. Animals were scanned on small animal
NanoPET/CT or NanoPET/MR scanners (Mediso Ltd., Budapest,
Hungary) [24] with identical PET components. The CT was used for at-
tenuation correction and the MR scan for co-registration purposes.
Next, a dynamic emission scan of 60minwas acquired immediately fol-
lowing administration of 3.77 ± 0.58 MBq of [18F]3-d7. Dynamic scans
were acquired in list mode and rebinned into the following frame se-
quence: 4 × 5 s, 4 × 10 s, 2 × 30 s, 3 × 60 s, 2 × 300 s, 3 × 600 s, 1 × 900 s.
Reconstruction of nanoPET emission scans was performed using an
iterative 3D Poisson ordered-subsets expectation-maximization algo-
rithm (Tera-Tomo; Mediso Ltd. [24]) with 4 iterations and 6 subsets,
resulting in an isotropic 0.4 mm voxel dimension. The reported spatial
resolution of the scanners is 1 mm2. PET images were analyzed using
the freely available AMIDE software (version 0.9.2) [25]. Ellipsoidal
shaped whole brain ROIs were drawn manually, based on anatomical
structure indicated by the MR or CT scan. These ROIs were projected
onto the dynamic image sequences, generating whole brain time-
activity curves (TACs). All TACswere expressed asmean of standardized
uptake values (SUV) within the VOI. SUV is a unitless parameter
resulting from the normalization of the measured activity to injected
dose and body weight.
3. Results & discussion
In a previous study, two ﬂuorine-18 labeled verapamil analogs were
evaluated, [18F]1 and [18F]2 [6]. Although in vivo results showed P-gpTable 2
Parent tracer and radiolabeled metabolite fractions in brain tissue (% of total radioactivity, me
structures, see Fig. 1.
Min [18F]1 [18F]1 d4
Parent tracer 5 41 ± 10% 55 ± 6%
15 14 ± 2% 27 ± 1%
60 2 ± 0.3% 0.2 ± 0.1%
Brain metabolites 5 59 ± 10% 36 ± 24%
15 86 ± 2% 73 ± 1%
60 98 ± 0.3% 100 ± 0.1%substrate behavior,metabolism of both tracers was increased compared
with (R)-[11C]verapamil. As rapid metabolism may compromise both
signal to noise ratios and quantitative analysis, the purpose of the pres-
ent study was to assess whether metabolic stability could be improved
using deuterium substitution, an approach that has been successful for
other tracers [18–21]. Four new analogs were synthesized and evalu-
ated (Fig. 1). [18F]1-d4 and [18F]2-d4 were exact deuterium substituted
analogs of [18F]1 and [18F]2, with four deuterium atoms substituted on
the ﬂuoroethyl group. To gain more insight in the role of the original
amine bound methyl group of verapamil, two other analogs of [18F]2
were synthesized, [18F]3-d3 and [18F]3-d7, both with a deuterated
methyl group. The difference between these two analogs was the
(non-)deuterated ﬂuoroethyl group.3.1. Chemistry
The syntheses of the precursors and reference compoundswere almost
identical to those of the non-deuterated compounds, which have been de-
scribed previously [6]. The use of commercially available deuterated
starting materials ethylene-d4 glycol and 2-bromoethanol-1,1,2,2-d4 re-
sulted in straightforward syntheses and ensured reliable isotopic purity.
Ethylene-d4 glycol was di-tosylated with tosylchloride (Scheme 1)
to be directly linked to the Boc-protected phenyl amine 8 (Scheme 2).
The deprotected amine 10 was coupled to the (R)-aldehyde 15 as de-
scribed previously [6] and it was directly protected with a Boc group
to prevent formation of dimers, resulting in the precursor 17 of tracer
[18F]2-d4 (Scheme 3).
To synthesize the deuterated reference compound 18 of [18F]2-d4
the tosyl group on the Boc protected amine 9 was ﬂuorinated with
TBAF to form amine 11. After deprotection, amine 12 was coupled to
aldehyde 15 by reductive amination, resulting in the reference com-
pound 18.
The two precursors 16 and 19 of [18F]3-d3 and [18F]3-d7, respec-
tively, were synthesized from aldehyde 15 and the (deuterated) amines
13 and 10. After reductive amination, the secondary amine wasmethyl-
ated with Iodomethane-d3 (Scheme 3). The two precursors 16 and 19
were both very difﬁcult to purify and preparative HPLC was needed.
Due to this extra step a lot of material was lost resulting in low yields.
In future studies, this step needs to be optimized.an ± SD; after intravenous injection of tracers under isoﬂurane anesthesia); for chemical
[18F]2 [18F]2 d4 [18F]3 d3 [18F]3 d7
26 ± 6% 46 ± 4% 50 ± 6% 60 ± 6%
17 ± 7% 34 ± 4% 26 ± 4% 38 ± 3%
6 ± 1% 11 ± 2% 7 ± 0.2% 8 ± 2%
74 ± 6% 54 ± 4% 50 ± 6% 40 ± 6%
83 ± 7% 64 ± 1% 74 ± 4% 62 ± 3%
94 ± 1% 89 ± 2% 93 ± 0.2% 92 ± 2%
Fig. 3.Whole brain time-activity curves of a) [18F]3 d7, b) (R) [11C]verapamil and c) [18F]2 in●wild-type (WT) mice and■Mdr1a/b(−/−) mice [6]. d) Ratio ofMdr1a/b(−/−) SUV overWT
SUV with▲[18F]3 d7, ■ [18F]2 and ● (R) [11C]verapamil. Mice were injected with 3–4 MBq of [18F]3 d7 under isoﬂurane anesthesia for 60 min.
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[18F]2 was used [6] and methylated with Iodomethane-d3.
Since the reference compoundwas used to identify the tracers by co-
elution on analytical HPLC, the effect of deuterium substitution on elu-
tion time was tested. No difference in elution time between [18F]2 and
[18F]2-d4was observed for differentHPLC systems and therefore the ref-
erence compound of [18F]1 could be used for [18F]1-d4 and the reference
compound of [18F]3-d3 for [18F]3-d7.
3.2. Radiochemistry
2-Bromoethanol-d4 was tosylated (Scheme 1) and the puriﬁed oil
was used as such to synthesize [18F]1-d4 (Scheme 4). For [18F]1-d4, the
same method was used as described before [6], where 2-
bromoethyltosylate-d4 was ﬂuorinated and distilled to a second vial.
On average 25%of [18F]21was distilled to the second vial. The conversion
of the second step to [18F]1-d4, varied from5 to 27% and stirringwas nec-
essary to obtain product with a total yield of 2.64 ± 2.26% DC (n= 7).
This resulted in enough product to perform animal experiments.
[18F]2-d4 was radiolabeled as previously described [6], with direct
ﬂuorination and deprotection of the Boc group to result in a total yield
of 6.10 ± 2.62% DC (n= 3) (Scheme 5).
[18F]3-d3 and [18F]3-d7 were radiolabeled in exactly the same
manner, i.e. by direct ﬂuorination on the tosyl group. Puriﬁcation was
challenging since traces of unlabeled ﬂuorine were found in the
product. To circumvent this, a puriﬁcation step with an Alumina Sep-
Pak was introduced to trap free and unreacted [18F]ﬂuorine on the
Sep-Pak, before HPLC puriﬁcation. This resulted in collected product
with a radiochemical purity N99.5% and a total yield of 2.74 ± 0.71%
DC (n = 3) and 4.90 ± 3.86% DC (n = 5) for [18F]3-d3 for [18F]3-d7,
respectively. As the precursors were not 99.9% pure, an additionalradiochemical purity check was included using an HPLC system with a
different column and eluent.
3.3. Metabolite study
Metabolite analyses of four novel tracers were performed in healthy
Wistar rats, 5, 15 and 60 min after tracer injection. As the focus of the
present study was on the comparison of stabilities of analog
compounds, only male animals were used in order to avoid possible
variation due to gender differences. In order to exclude possible differ-
ences in in vivo behavior of the tracers due to gender differences, a
follow-up study should be performed for the most promising analog.
This is beyond the scope of the present study. Statistical analysis of the
metabolite data was performed using two-tailed unpaired t-tests. For
plasma (Table 1), no improvement in metabolic stability was observed
when moving from the hydrogenated to the deuterated [18F]1 tracer.
On the other hand, for the [18F]2(-d4) analogs, an signiﬁcant improve-
ment in stability due to the deuterated ﬂuoroethyl group was observed
(p b 0.05, for 5 and 15 min). This could indicate that a different meta-
bolic pathway for N-deﬂuorethylation takes place, where the C\\D
bond is not included in the rate limiting step. Nonetheless, [18F]2-d4
was less stable in plasma than non-deuterated [18F]1. It seems that the
tertiary amine slows down the metabolic rate, possibly by steric hin-
drance. To test this hypothesis, a deuterated methyl group on the
amine was added in additional analogs, i.e. [18F]3-d3 and [18F]3-d7,
without andwith the deuterated ﬂuoroethyl group on the phenolic side.
The addition of a deuterated methyl group on the amine showed
even higher in vivo stability. This actually contradicts the ﬁrst assump-
tion in the design of [18F]2 [6], which was based on the postulation
that removal of the methyl group would circumvent the ﬁrst metabolic
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metabolites, which may also act as substrates of P-gp. For almost all
tracers, primarily polar metabolites were formed, which are not ex-
pected to penetrate the BBB and therefore will not interfere with the
PET signal. Interestingly, [18F]3-d7 showed a different pattern with
more labeled non-polar metabolites in plasma. This might reﬂect a me-
tabolite that is formed after metabolic cleavage of the C\\N bond on the
stereoselective side of the molecule, with the deuterated methyl group
still attached.
Brain tissue showed a different distribution between parent tracer
and metabolites because some metabolites do not cross the blood-
brain barrier. In the brain (Table 2), signiﬁcantly more parent [18F]1-d4
is present comparedwith [18F]1 (p b 0.0005 at 15min). For [18F]2, an in-
creased parent fraction for the deuterated analog is evenmore prevalent
(p b 0.05 at 5 and 15min). Similar to the pattern in plasma, the combina-
tion of deuterated methyl and ﬂuoroethyl groups ([18F]3-d7) results in
the highest fraction of parent tracer, until the 60 min time point, when
[18F]2-d4 showed the highest parent fraction in the brain.
3.4. PET study
To assess in vivo behavior, a PET studywas performed in control and
Mdr1a/b(−/−) mice with the overall metabolically most stable
tracer [18F]3-d7 (Fig. 4). Increased brain uptake was observed in
Mdr1a/b(−/−) mice compared with wild type mice (Fig. 3a). Washout
was slow and similar to that of (R)-[11C]verapamil in the brain
(Fig. 3b). The ratio in whole brain uptake between Mdr1a/b(−/−)
and wild type mice was signiﬁcantly higher for [18F]3-d7 than for [11C]
verapamil (p= 0.0067, paired t-test) (Fig. 3c). Data from the previous
study [6] with the same PET experiments shows a different pattern for
[18F]2, where steady brain uptake was seen (although SUV remained
below 1) without appreciable washout. This could be caused by the ad-
ditional (deuterated) methyl group and consequently difference in log
D (1.61 and 2.19 for [18F]2 and [18F]3-d7, respectively (Table 3)), sug-
gesting that the methyl group affects in vivo behavior and (in this






Fig. 4.Representative horizontal brain PET/CT images of [18F]3 d7 inWT andMdr1a/b(−/−)
mice.Related to the lipophilicity, plasma protein binding could be an
important factor for successful clinical implementation of a PET tracer.
(R)-[11C]verapamil showed 88% plasma protein binding in human
plasma [26], which did not limit its use for imaging. In general, high li-
pophilic PET tracers show high plasma protein binding [27]. Since all
tracers developed are structurally similar to verapamil, but lower in li-
pophilicity (Table 3), no problems are expected with respect to plasma
protein binding. To resolve the true value of the new PET tracer [18F]3-
d7, clinical studies are needed. Possible study limitations for translation
might be a different route of administration in the clinic, difference in
metabolism between species and a laborious precursor syntheses route.
In the present study, no assessment of speciﬁcity toward P-gp in
comparison with other transporters was performed. However, both
(R)-[11C]verapamil and [18F]2 are speciﬁc for P-gp, and this is also ex-
pected for the structurally similar analog [18F]3-d7.
4. Conclusion
The metabolic stability of existing ﬂuorine-18 labeled verapamil an-
alogs can be improved by inclusion of deuterium in the tracer molecule.
In addition, increased metabolic stability of the methyl containing ana-
logs [18F]3-d3 and [18F]3-d7 was observed, which may be the result of
steric hindrance of enzymatic metabolism. The similarity of in vivo be-
havior between [18F]3-d7 and (R)-[11C]verapamil, together with im-
proved metabolic stability of [18F]3-d7, compared to the other
ﬂuorine-18 labeled tracers, supports the potential of [18F]3-d7 as a can-
didate for clinical translation as a ﬂuorine-18 labeled PET tracer for eval-
uation of P-gp.
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